News
DHR
248.77
+0.23%
0.58
Danaher (DHR) Rises Yet Lags Behind Market: Some Facts Worth Knowing
NASDAQ · 16h ago
Wall Street Analysts See Danaher (DHR) as a Buy: Should You Invest?
NASDAQ · 1d ago
Possible Bearish Signals With Danaher Insiders Disposing Stock
Danaher Corporation insiders have sold US$1.9m worth of shares in the last year. The biggest single sale by an insider at Danaher was by Linda Filler, who sold shares at a price of US$260 per share. In the last 12 months, Danaher insiders didn't buy any shares. The company owns 6.8% of Danaher. Danaher has no insider transactions over the past year.
Simply Wall St · 1d ago
Danaher: All In On Life Sciences, And Market Update
Danaher Corporation (DHR) is a leading player in the life science industry. The healthcare industry is facing challenges due to weak funding and high vacancy rates in lab spaces. Danaher has spun-off three companies in the past 10 years. The company has a strong financial performance despite many spin-offs.
Seeking Alpha · 1d ago
Danaher (DHR) Gains As Market Dips: What You Should Know
NASDAQ · 1d ago
Looking Into Danaher's Recent Short Interest
Danaher's short percent of float has fallen 5.38% since its last report. The company has 5.80 million shares sold short, which is 0.88% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 1d ago
The Health Care Select Sector SPDR Fund Experiences Big Outflow
NASDAQ · 2d ago
Danaher on Pace for Largest Percent Decrease Since October 2023 -- Data Talk
Danaher Corporation (DHR) is currently at $247.95, down $6.85 or 2.69%. Down 15.85% from its all-time closing high of $294.66. Down 2.05% month-to-date; on pace for worst month since Oct. 2023.
Dow Jones · 3d ago
If You Invested $100 In This Stock 10 Years Ago, You Would Have $500 Today
Danaher has outperformed the market over the past 10 years by 6.72% on an annualized basis. The company has an average annual return of 17.41%. Danaher has a market capitalization of $188.46 billion. If an investor bought $100 of DHR stock 10 years ago it would be worth $499.37 today.
Benzinga · 3d ago
Weekly Report: what happened at DHR last week (0318-0322)?
Weekly Report · 3d ago
GE HealthCare Technologies: Growth Prospects Remain Encouraging, And Valuation Is Attractive
GE Healthcare Technologies Inc. Is expected to experience good revenue and margin growth moving forward. The company's revenue growth will be supported by pent-up demand for procedures and strong end-market demand. New product innovations and a tuck-in M&A strategy will also contribute to sales growth. GEHC stock is trading at a significant discount to its peers with similar growth prospects. I continue to have a buy rating on the stock.
Seeking Alpha · 3d ago
Dividend Champion, Contender, And Challenger Highlights: Week Of March 24
Home Dividends Analysis Dividend Quick Picks: Week of March 24. Justin Law's weekly summary of dividend activity for D dividend Champions, Contenders, and Challengers. This week, he highlights recent and upcoming dividend related activity for dividend stocks on the D dividend champions list.
Seeking Alpha · 4d ago
Danaher Schedules First Quarter 2024 Earnings Conference Call
Danaher Corporation will webcast its quarterly earnings conference call for the first quarter 2024 on Tuesday, April 23, 2024. The company will discuss its financial performance and future expectations. The call and slide presentation will be webcast on the company's website. A replay of the conference call will be available shortly after the call.
PR Newswire · 6d ago
20 Upcoming Dividend Increases To Finish Q1
20 new dividend increases with an average increase of 8.5% and a median of 8% are shared. I have compiled a list of top stocks expected to raise dividends in the upcoming week. Companies that regularly raise their dividends perform better than those that do not. Home Dividends Analysis has 20 new dividend Increases to finish out the first quarter of 2024.
Seeking Alpha · 6d ago
Revvity: Enter Now As Reorganization Takes Shape
Revvity, Inc. Is a major laboratory instrument and service provider to the healthcare industry. The company has historically underperformed compared to its peers in terms of profit generation and growth. Revvity has implemented a business restructuring plan and aims to drive differentiation through inorganic investments in high-margin areas. Over the past 20 years the company has returned 10.5% per year for investors.
Seeking Alpha · 6d ago
Boeing CEO Calhoun Might Have to Go. Three Who Could Replace Him.
Boeing CEO Dave Calhoun is under pressure after another 737 MAX production problem. Calhoun has been in the job for four years. Who will succeed him? Boeing's stock is down 40% since Calhoun was named CEO in 2013. Some analysts say an outsider with manufacturing expertise could be a good choice.
Barron‘s · 03/21 11:29
Danaher (DHR) Stock Declines While Market Improves: Some Information for Investors
NASDAQ · 03/20 22:00
Cytek Biosciences: Undisputed Next-Gen Flow Cytometry Leader
Cytek Biosciences is a leading cellular analysis instrument maker with a focus on the Aurora flow cytometry platform. Despite a downturn in the healthcare market, Cytek has maintained revenue growth above 15% since IPO. Cytek's technological advantage, broadening ecosystem, and potential in the clinical and biopharma space contribute to the positive outlook.
Seeking Alpha · 03/20 08:33
IP’s stock jumps after replacing longtime CEO with an investment-firm veteran
MarketWatch · 03/19 16:16
Why Danaher (DHR) Outpaced the Stock Market Today
NASDAQ · 03/18 22:15
More
Webull provides a variety of real-time DHR stock news. You can receive the latest news about Danaher Corporation through multiple platforms. This information may help you make smarter investment decisions.
About DHR
Danaher Corporation is a global life sciences and diagnostics innovator. The Company operates through three business segments: Biotechnology, Life Sciences and Diagnostics. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a broad range of equipment, consumables and services that are primarily used by customers to advance and accelerate the research, development, manufacture and delivery of biological medicines. The Life Sciences segment offers a range of instruments, consumables, services and software that are primarily used by customers to study genomics and the basic building blocks of life, including deoxyribonucleic acid (DNA)and ribonucleic acid (RNA), nucleic acid, proteins, metabolites and cells. The Diagnostics segment offers clinical instruments, consumables, software and services that hospitals, physicians’ offices, reference laboratories and other critical care settings use to diagnose disease and make treatment decisions.